BioSpace News Archive

Swedish biotech company Salipro Biotech AB announced that it has entered into a research collaboration with Sumitomo Pharma Co., Ltd. to reveal the mechanism of action and pharmacological characterization of a drug candidate.

CancerVAX, Inc. announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies.

AlgoTherapeutix announces it has dosed the first patients of up to 14, in the US and European centers of its phase II proof of concept trial, called EASE*.

HUTCHMED Limited announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor exon 14 skipping alteration non-small cell lung cancer, were presented during the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, which took place from September 9 to 12, 2023 in Singapore.

Zura Bio Limited and Benaroya Research Institute announced that they have entered into a sponsored research agreement focused on further characterizing the pivotal role of Interleukin-7 receptor alpha in Thymic Stromal Lymphopoietin and Interleukin-7 signaling pathways.

BC Platforms, a global leader in healthcare data management and analytics, announces the appointment of Mikaela Bruhammar, an experienced life sciences executive, as the company’s Chief Operating Officer, Markets.

Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer.

CancerX, the public-private partnership that launched in March of this year to harness the power of innovation to help achieve the goals of the Cancer Moonshot, announced its inaugural steering committee and strategic priorities.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery.

Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series).